Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372:1887–97.

Article  PubMed  PubMed Central  Google Scholar 

Binks M. Pfizer gene therapy (PF-06939926) in Duchenne muscular dystrophy. In: Workshop on Systemic Immunogenicity Considerations for AAV-mediated Gene Therapy (National Center for Advancing Translational Sciences); November 30–December 1. Virtual; 2021.

Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20:361–9.

Article  CAS  PubMed  Google Scholar 

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kishnani PS, Sun B, Koeberl DD. Gene therapy for glycogen storage diseases. Hum Mol Genet. 2019;28:R31–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.

Article  PubMed  PubMed Central  Google Scholar 

Maguire AM, Russell S, Wellman JA, Chung DC, Yu Z-F, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation–associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273–85.

Article  PubMed  Google Scholar 

Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–22.

Article  CAS  PubMed  Google Scholar 

Murillo O, Moreno D, Gazquez C, Barberia M, Cenzano I, Navarro I, et al. Liver expression of a MiniATP7B gene results in long-term restoration of copper homeostasis in a Wilson disease model in mice. Hepatology. 2019;70:108–26.

Article  CAS  PubMed  Google Scholar 

Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994–2004.

Article  PubMed  PubMed Central  Google Scholar 

Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382:29–40.

Article  CAS  PubMed  Google Scholar 

Raper SE, Yudkoff M, Chirmule N, Gao G-P, Nunes F, Haskal ZJ, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 2002;13:163–75.

Article  CAS  PubMed  Google Scholar 

Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013;24:630–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan W-H. AAV8 gene therapy as a potential treatment in adults with late-onset OTC deficiency: results from a phase 1/2 clinical trial. The American Society of Gene & Cell Therapy 23rd Annual Meeting; 12–15 May 2020. Virtual.

Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255–62.

Article  CAS  PubMed  Google Scholar 

Ylä-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012;20:1831–32.

Article  PubMed  PubMed Central  Google Scholar 

Heo YA. Etranacogene Dezaparvovec: first approval. Drugs. 2023;83:347–52.

Article  CAS  PubMed  Google Scholar 

Blair HA. Valoctocogene Roxaparvovec: first approval. Drugs. 2022;82:1505–10.

Article  PubMed  Google Scholar 

Ronzitti G, Gross D-A, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11:670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28:723–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704–12.

Article  CAS  PubMed  Google Scholar 

Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–90.

Article  PubMed  Google Scholar 

Calcedo R, Wilson JM. AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees. Hum Gene Ther Clin Dev. 2016;27:79–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59:406–11.

Article  CAS  PubMed  Google Scholar 

Perocheau DP, Cunningham S, Lee J, Antinao Diaz J, Waddington SN, Gilmour K, et al. Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort. Hum Gene Ther. 2019;30:79–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther. 2010;18:126–34.

Article  CAS  PubMed  Google Scholar 

Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther. 2022;33:432–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 2006;108:3321–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long BR, Sandza K, Holcomb J, Crockett L, Hayes GM, Arens J, et al. The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy. Mol Ther Methods Clin Dev. 2019;13:440–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–7.

Article  CAS  PubMed  Google Scholar 

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood. 2006;107:1810–7.

Article  CAS  PubMed  Google Scholar 

Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22:1389–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuranda K, Jean-Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Invest. 2018;128:5267–79.

Article  PubMed  PubMed Central  Google Scholar 

Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13:419–22.

Article  CAS  PubMed  Google Scholar 

Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876–85.

Article  CAS  PubMed  PubMed Central  Google Scholar